Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses in Italian high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)
Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non-small cell lung cancer previously treated with chemotherapy and crizotinib. (Abstract LBA42)
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)
Janessa J. Laskin, MD, of the British Columbia Cancer Agency, discusses the ways in which availability of tumor gene expression data facilitates clinical decision-making for patients with advanced cancers. (Abstract 1519O)
Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses in French phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)
